Skip to main content

Table 1 Patients' and tumor characteristics

From: Comparison of definite chemoradiation therapy with carboplatin/paclitaxel or cisplatin/5-fluoruracil in patients with squamous cell carcinoma of the esophagus

Parameter Intention to treat analysis Per protocol analysis
Carb/TAX
n = 22
CDDP/5FU
n = 25
p-value Carb/TAX
n = 18
CDDP/5FU
n = 23
p-value
Median Age
(IQR)
68
(62–74)
66
(62–69)
0.149 68
(62–72)
66
(58–69)
0.337
Male 15 (68%) 21 (84%) 0.303 13 (72%) 19 (83%) 0.471
T-stage 0.247    0.265
 uT1 1 (5%) 0 (0%)   1 (6%) 0 (0%)  
 uT2 4 (18%) 2 (8%)   4 (22%) 2 (9%)  
 uT3 16 (73%) 27 (72%)   12 (67%) 17 (74%)  
 uT4 1 (5%) 5 (20%)   1 (6%) 4 (17%)  
uN+ 21 (95%) 23 (92%) 1.000 17 (94%) 21 (91%) 1.000
cM0 22 (100%) 24 (96%) 1.000 18 (100%) 22 (96%) 1.000
Grading 0.756    0.515
 G2 11 (61%) 13 (52%)   9 (64%) 12 (52%)  
 G3 7 (39%) 12 (48%)   5 (36%) 11 (48%)  
Median tumor extension (cm)
(IQR)
5
(3–7)
5
(5–7)
0.216 5
(3–6)
5
(5–6)
0.108
Median radiation dose (Gy)
(IQR)
59.4
(55.8–59.4)
54.0
(54.0–54.0)
< 0.001 59.4
(54.0–59.4)
54.0
(54.0–54.0)
< 0.001
Median daily radiation dose (Gy)
(IQR)
1.8
(1.8–1.8)
1.8
(1.8–1.8)
0.253 1.8
(1.8–1.8)
1.8
(1.8–2.0)
0.429
  1. 5-FU 5-fluoruracil, IQR inter-quartiles-range, Gy gray